多瑞醫藥(301075.SZ):子公司擬受讓和認購基金份額
格隆匯8月20日丨多瑞醫藥(301075.SZ)公佈,子公司武漢吉瑞健康產業投資有限公司(簡稱“吉瑞健康”)與自然人程志庭簽訂《財產份額轉讓協議書》,以300萬元受讓其持有的深圳市倚鋒睿景創業投資合夥企業(有限合夥)(簡稱“倚鋒睿景”)300萬元的財產份額(實繳出資300萬元);同時,吉瑞健康與倚鋒睿景簽訂《合夥協議》,以700萬元認購其700萬元的財產份額。本次交易後,吉瑞健康合計持有倚鋒睿景1,000萬元的財產份額,出資比例為9.9990%。
基金管理人倚鋒投資是國內第一批生物醫藥專業投資機構,專注於創新藥和高端醫療器械領域投資。公司藉助專業投資機構在行業分析、投資標的篩選及價值發現方面的專業能力、經驗和資源,結合公司發展方向多方位探索新的利潤增長點,進一步提升公司綜合競爭力和盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.